Helix Holdings II LLC - 11 Aug 2025 SCHEDULE 13D/A Report for BridgeBio Oncology Therapeutics, Inc. Common Stock (HLXB)

Filing Manager
Helix Holdings II LLC
Reporting Manager
Bihua Chen
Security
BridgeBio Oncology Therapeutics, Inc. Common Stock
Symbol
HLXB
Shares outstanding
79,108,823 shares
Disclosed Ownership
17,878,594 shares
Ownership
23%
Form type
SCHEDULE 13D/A
Filing time
13 Aug 2025, 08:29:42 UTC
Date of event
11 Aug 2025
SEC
View on sec.gov

Quoteable Key Fact

"Helix Holdings II LLC disclosed 23% ownership in BridgeBio Oncology Therapeutics, Inc. Common Stock (HLXB) on 11 Aug 2025."

Quick Takeaways

  • Helix Holdings II LLC filed SCHEDULE 13D/A for BridgeBio Oncology Therapeutics, Inc. Common Stock (HLXB).
  • Disclosed ownership: 23%.
  • Date of event: 11 Aug 2025.

What Changed

  • No earlier schedule filing is available for direct comparison.
  • Current filing was accepted on 13 Aug 2025, 08:29.

Why This Matters

  • This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
  • You can verify ownership claims directly against the original SEC filing.

Source Evidence

Backed by Schedule 13D/13G

Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.

See Original Filing

Reporting Managers (4)

Name Ownership Shares Owned sole voting power shared voting power Signature Title CIK
Helix Holdings II LLC 5.7% 4,528,186 4,528,186 0 /s/ Bihua Chen Bihua Chen, Managing Member 0001869101
Cormorant Global Healthcare Master Fund, LP 7.5% 5,952,356 5,952,356 0 /s/ Bihua Chen Bihua Chen, Managing Member of Cormorant Global Healthcare GP, LLC 0001618442
Cormorant Global Healthcare GP, LLC 7.5% 5,952,356 5,952,356 0 /s/ Bihua Chen Bihua Chen, Managing Member 0001618451
Bihua Chen 23% 17,878,594 17,878,594 0 /s/ Bihua Chen Bihua Chen, Self 0001599214